Hepatocyte Growth Factor Receptor (MET) Antibody (HRP)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
MET Antibody (HRP) is a Rabbit Polyclonal against MET conjugated to HRP.
Documents del producto
Product specifications
Category | Primary Antibodies |
Immunogen Target | Hepatocyte Growth Factor Receptor (MET) |
Host | Rabbit |
Reactivity | Human |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Polyclonal |
Conjugation | HRP |
Isotype | IgG |
Purity | > 95% |
Purification | Purified by Protein G. |
Size 1 | 20 µg |
Size 2 | 50 µg |
Size 3 | 100 µg |
Size 4 | 200 µg |
Size 5 | 1 mg |
Form | Liquid |
Tested Applications | ELISA |
Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
Availability | Shipped within 5-10 working days. |
Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | P08581 |
Gene ID | 4233 |
NCBI Accession | NP_000236.2 |
OMIM | 114550 |
Background | Antibody anti-MET |
Status | RUO |
Descripción
Related Products

MET antibody
c-Met(also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target(PMID: 26036285). This antibody recognizes the N-term of c-Met.
Ver Producto
MET antibody
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis(By similarity). Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells.
Ver Producto